Beat obesity with safe, non-surgical weight loss treatment

New York, April 4 (IANS) Obese people struggling with weight loss can now opt for safe, minimally invasive, non-surgical weight-loss treatments, finds a new study.

Radiologists have developed a new image-guided treatment called bariatric arterial embolisation (BAE), which blocks blood flow to a certain part of the stomach that could help obese patients lose weight.

“Currently, interventions to treat obesity include behavioural modifications, diet and exercise, medications and surgery. We’re excited about the promise of BAE as another tool for health care providers to offer patients in the effort to curb this epidemic,” said Clifford Weiss, associate professor at Johns Hopkins University in US.

The findings showed that compared to a surgical gastric bypass procedure, BAE is significantly less invasive and has a much shorter recovery time.

Though the results are still preliminary, BAE appears to be effective in helping patients lose a significant amount of weight in the short and intermediate term.

All patients demonstrated weight loss and dramatic hunger reduction levels after undergoing the treatment.

The participants showed an average excess-weight loss of 5.9 percent, after a month.

After six months, the excess-weight loss increased to an average of 13.3 percent.

The treatment starts by feeding a small catheter through a patient’s arteries, via an incision in either the groin or the wrist, to an area at the top of the stomach called the fundus, where the hunger-stimulating hormone ghrelin is produced. Tiny beads are injected through the catheter to decrease blood flow to the fundus.

For the pilot study, the team enrolled seven severely obese, but otherwise healthy, adults with a body mass index (BMI) ranging from 40 to 60, far above the obesity threshold level of BMI of 30.

After the treatment, researchers tracked the subjects’ weight loss, ghrelin levels, hunger and satiety assessments, quality-of-life (using surveys), blood pressure, and adverse events at one-, three- and six-month marks.

In these first seven patients, bariatric embolisation was safe, with no major adverse events. There was weight loss and dramatic reduction in hunger levels. Also, ghrelin levels toned down and quality-of-life scores improved.

The study was presented at the ongoing Society of Interventional Radiology’s 2016 Annual Scientific Meeting in Vancouver, Canada.

Leave a Reply

Please enter your comment!

The opinions, views, and thoughts expressed by the readers and those providing comments are theirs alone and do not reflect the opinions of www.mangalorean.com or any employee thereof. www.mangalorean.com is not responsible for the accuracy of any of the information supplied by the readers. Responsibility for the content of comments belongs to the commenter alone.  

We request the readers to refrain from posting defamatory, inflammatory comments and not indulge in personal attacks. However, it is obligatory on the part of www.mangalorean.com to provide the IP address and other details of senders of such comments to the concerned authorities upon their request.

Hence we request all our readers to help us to delete comments that do not follow these guidelines by informing us at  info@mangalorean.com. Lets work together to keep the comments clean and worthful, thereby make a difference in the community.

Please enter your name here